NewsSOS
Johnson & Johnson will not pursue the obesity drug market, Chief Executive Joaquin Duato said, opting instead to build the company into what he described as the world's leading cancer company.
The move sets J&J apart from rivals scrambling to develop or acquire weight-loss medicines in the wake of blockbuster treatments from Eli Lilly and Novo Nordisk.
Food and Drug Administration approved GSK's oral antibiotic Utebzi for complicated urinary tract infections caused by drug-resistant bacteria.
J&J Doubles Down on Oncology Duato's remarks position oncology as one of J&J's core growth pillars following the company's spin-off of its Kenvue consumer health business.
Keep reading